Benitec Biopharma announced positive interim Phase 1b/2a clinical results for BB-301, showing a 100% responder rate in patients with Oculopharyngeal Muscular Dystrophy-related dysphagia, with no serious adverse events reported. The pivotal trial for BB-301 is on track to begin in mid-2027. Financially, the company reported a net loss of $12.9 million for Q1 2027 fiscal year, with increased R&D expenses reflecting ongoing clinical development, and held $176.5 million in cash as of September 30, 2026. Benitec also plans to shift its fiscal year-end from June 30 to December 31 starting this year.
Benitec Biopharma's recent financial and clinical update provides context for readers following health sector developments. For readers following health stocks, here is Pluang's market snapshot as of Nov 13, 2026 19:41 WIB: Among 150 priced health-sector US stocks tradable on Pluang, 99 rose and 43 fell today. Notable movers include NVAX (Novavax Inc) at USD 8.96 with a 1-day change of +2.28% and Pluang order activity of 1% Sell / 99% Buy, COO (The Cooper Companies Inc.) at USD 63.52 with a 1-day change of +2.14%, and TVTX (Travere Therapeutics Inc.) at USD 52.57 with a 1-day change of +1.96%.
Michelin has announced the total number of its voting rights and shares as of October 31, 2026. The company has 691,516,292 shares and 960,075,649 voting rights, considering 20,287,710 treasury shares. This disclosure complies with French regulations...
Michelin has disclosed the total number of voting rights and shares composing its capital as of October 31, 2026. The company reported 691,516,292 shares, with theoretical voting rights totaling 980,363,359 and exercisable voting rights at 960,075,64...
KeyBanc lowered its price target for YETI Holdings to $49, suggesting a 27.94% upside from the current $38.30 stock price. This follows YETI's reduction of its full-year adjusted sales growth forecast to about 6% from the previous 7-8%, citing consum...
Bernstein SocGen Group has reduced its price target for Applied Materials to $600, even though the company reported higher sales and profits in Q4 2026 driven by strong demand for semiconductor services, especially AI chips. Applied Materials posted ...
Boralex Inc. announced a private placement of $600 million Canadian dollars in green bonds, split into two series maturing in 2031 and 2036 with interest rates of 4.503% and 5.173%, respectively. This marks Boralex's first issuance of green corporate...
